Cite
Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
MLA
Mansur, Rodrigo B., et al. “Cognitive Dysfunction and Metabolic Comorbidities in Mood Disorders: A Repurposing Opportunity for Glucagon-like Peptide 1 Receptor Agonists?” Neuropharmacology, vol. 136, July 2018, pp. 335–42. EBSCOhost, https://doi.org/10.1016/j.neuropharm.2018.01.048.
APA
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018). Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology, 136, 335–342. https://doi.org/10.1016/j.neuropharm.2018.01.048
Chicago
Mansur, Rodrigo B., Yena Lee, Mehala Subramaniapillai, Elisa Brietzke, and Roger S. McIntyre. 2018. “Cognitive Dysfunction and Metabolic Comorbidities in Mood Disorders: A Repurposing Opportunity for Glucagon-like Peptide 1 Receptor Agonists?” Neuropharmacology 136 (July): 335–42. doi:10.1016/j.neuropharm.2018.01.048.